Bone Cancer Information Center

Bone Cancer News

Shortened Interval Between Chemotherapy Cycles Does Not Improve Survival with Osteosarcoma (01/23/2007)
According to the results of a study published in the Journal of the National Cancer Institute, osteosarcoma patients treated with the chemotherapy drugs cisplatin and doxorubicin every two weeks did not have better survival than patients who received the same drugs every three weeks.

Heart Dysfunction Continues Long After Treatment with Adriamycin® (07/21/2006)
According to results published in the Annals of Oncology, childhood cancer survivors with bone cancer who were treated with Adriamycin® (doxorubicin) demonstrated declining heart function at 22 years following treatment.

Chemotherapy Combination Produces Promising Results in Ewing’s Sarcoma (04/05/2006)
Among patients with high-risk Ewing’s sarcoma family of tumors (ESFT), treatment with an intensified chemotherapy regimen of ifosfamide, carboplatin, and etoposide (ICE) plus cyclophosphamide, doxorubicin, and vincristine (CAV), resulted in good control of disease and made it easier to perform surgery. These results were published in the journal Cancer.

Computed Tomography (CT) Misses Large Portion of Cancer Spread to Lung in Osteosarcoma (02/07/2006)
According to a recent article published in the Journal of Pediatric Surgery, computed tomograhy (CT) scans miss over one-third of cancers that have spread to the lung in pediatric patients diagnosed with osteosarcoma.

Surgical Removal of Cancer Spread to the Lung Significantly Improves Survival in Osteosarcoma (02/07/2006)
According to a recent article published in the Journal of Pediatric Surgery, the surgical removal of cancer spread to the lung significantly improves survival among pediatric patients diagnosed with osteosarcoma.